Top Research Papers on Obesity

The rising prevalence of obesity is reviewed and potential mechanisms underlying its association with various comorbidities and how these respond to treatment are discussed, with a particular focus on cardiometabolic disease, malignancy and mental health.

A substantial body of literature demonstrates a paradox with improved prognosis of overweight and obese patients with established CVD compared to lean patients with the identical CVD, and the impact of fitness, exercise, physical activity, and weight loss and their relationship to the obesity paradox are reviewed.

Therapies including diet, medications, and bariatric surgery are discussed that should be considered in patients with BMIs if diet and lifestyle interventions fail to achieve weight loss and antihypertensive therapy, plasma lipid reduction and glucose lowering therapy should be prescribed in obese patients with hypertension, a 10-year CVD risk >7.5%, or prediabetes or diabetes.

These new guidelines will help to identify and manage high-risk groups for obesity-related comorbidities among Korean adults and put greater emphasis on the use of morbidity as the basis for obesity and abdominal obesity diagnoses.

This review aims to dissect the complexities of endogenous FGF21 and GDF15 action in obesity versus DIO resistance for the regulation of energy balance in metabolic health and disease.

Bariatric (metabolic) surgery remains the most effective and durable treatment, with proven benefits beyond weight loss, including for cardiovascular and renal health, and decreased rates of obesity-related cancers and mortality.

Dyslipidemia and obesity present common diseases that must be managed to decrease the cardiovascular risk and the risk of obesity-related complications.

Based on the 2011–2012 National Health and Nutrition Examination Survey, the prevalence of obesity in women of reproductive age (20–39 years) in the United States is 31.8% and increases to 58.5% when the overweight and obese categories are combined.

The purpose of this Practice Bulletin is to offer an integrated approach to the management of obesity in women of reproductive age who are planning a pregnancy.

Obesity is associated with increased morbidity. Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved weight loss and health outcomes.

C Cotreatment of obesity and diabetes requires a comprehensive medical approach that encompasses intensive lifestyle modification including behavioral changes, nutrition, and physical activity, as well as pharmacotherapy and possible surgical management.

The current evidence on obesity and menopause is reviewed, focusing on the implications of increased obesity duringMenopause, the impact of menoppause on obesity, and the effect of available treatments on associated morbidities.

Clinical and epidemiological studies, as well as data from experimental animal work, are being summarized to provide a state of the art update on this important topic.

Socioeconomic factors contribute to obesity on an individual and community level, and any viable approach to sustainably addressing the obesity epidemic must take these factors into account.

An overview of the literature addressing the association between obesity and T2DM is provided, briefly discussing the pathophysiological mechanisms linking these conditions and outlining the management approach at the overlap of obesity andT2DM.

Obesity has become a significant public health issue worldwide over the last four decades.[1] It is caused by excess body fat accumulation, which is harmful to health. Obesity is defined by the World Health Organization (WHO) as body mass index (BMI) ≥30 kg/m2, while overweight is the BMI of ≥25 kg/m2.[2] The prevalence of overweight and obesity is increasing globally in both developing and developed countries in all age groups.[3] Since 1980, globally, its prevalence is almost doubled.[4] The WHO has reported that in 2016, more than 1.9 billion adults were overweight; among them, 650 million ...

The roles and mechanisms of gut microbiota's composition and metabolite changes in the gut play in obesity and obesity related diseases are summarized and potential therapeutic treatments that can be used to modulate the gut microbiome composition and target the relevant metabolic pathways of Obesity and obesity-related metabolic diseases are discussed.

This review aims at providing a comprehensive update of the relationship between the adipose tissue in obesity and autoimmune disorders, highlighting the underlying mechanisms with a particular emphasis on adipokines and pro-inflammatory cytokines, the impaired B cell activity, and the production of natural and pathogenic autoantibody repertoire in the context of obesity.

Preclinical and clinical data are reviewed that contribute to explain the role of butyrate in this context, highlighting its crucial contribute in the diet-GM-host health axis.

This report might constitute a cornerstone by which to establish targets for future interventions for reversing the rise in the prevalence of obesity and reducing the burden of obesity in Korea.